UB-612
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Peptide subunit |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
UB-612 is a COVID-19 vaccine candidate developed by United Biomedical, Inc. Asia [zh], Vaxxinity (formerly known as COVAXX), and DASA.[1] It is a peptide vaccine.[2][3]
Technology[edit]
UB-612 is a peptide vaccine incorporating multiple epitopes, including the spike protein receptor binding domain as well as other virus structural proteins.[1][3] The spike protein peptide is fused to an Fc domain of single-chain IgG1, and the other six peptides are derived from highly conserved sequences from the spike, nucleocapsid, and membrane proteins of SARS-CoV-1 and SARS-CoV-2. It also contains a proprietary UBITh1 peptide derived from the measles virus fusion protein, CpG oligonucleotides, and aluminum phosphate adjuvant to improve the immune response. It is produced in CHO cells.[2]
Clinical trials[edit]
In September 2020, UB-612 started phase I clinical trials in Taiwan.[4]
In January 2021, UB-612 started phase II clinical trials in Taiwan.[5]
In February 2021, UB-612 started phase II/III clinical trials.[6]
References[edit]
- ^ a b Liao G (27 June 2021). "Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts". Taiwan News. Retrieved 8 July 2021.
- ^ a b Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L (12 July 2021). "SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants". Frontiers in Immunology. 12: 701501. doi:10.3389/fimmu.2021.701501. PMC 8311925. PMID 34322129.
- ^ a b "COVID-19 Vaccine". Vaxxinity. Retrieved 9 October 2021.
- ^ Clinical trial number NCT04545749 for "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
- ^ Clinical trial number NCT04683224 for "A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
- ^ Clinical trial number NCT04773067 for "A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers " at ClinicalTrials.gov
External links[edit]
Scholia has a profile for UB-612 (Q100158046). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
- Articles with short description
- Short description is different from Wikidata
- Use dmy dates from April 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles